Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 285491, 14 pages
http://dx.doi.org/10.1155/2015/285491
Research Article

The 482Ser of PPARGC1A and 12Pro of PPARG2 Alleles Are Associated with Reduction of Metabolic Risk Factors Even Obesity in a Mexican-Mestizo Population

1Instituto de Investigación en Reumatología y del Sistema Musculo Esquelético, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada No. 950, Colonia Independencia, 44340 Guadalajara, JAL, Mexico
2Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada No. 950, Colonia Independencia, 44340 Guadalajara, JAL, Mexico
3Servicio de Reumatología, Hospital Civil “Dr. Juan I. Menchaca”, Salvador Quevedo y Zubieta No. 750, Colonia Independencia, 44340 Guadalajara, JAL, Mexico
4UDG-CA-701, Grupo de Investigación Inmunometabolismo en Enfermedades Emergentes (GIIEE), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada No. 950, Colonia Independencia, 44340 Guadalajara, JAL, Mexico
5Tecnológico de Monterrey, Campus Guadalajara, Avenida General Ramón Corona No. 2514, Colonia Nuevo México, 45201 Zapopan, JAL, Mexico
6Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Boulevard Marcelino García Barragán 1421, 44430 Guadalajara, JAL, Mexico
7HMIELM, Secretaria de Salud Jalisco, Avenida Constituyentes 1075, Colonia Moderna, 44190 Guadalajara, JAL, Mexico

Received 1 September 2014; Revised 19 November 2014; Accepted 23 November 2014

Academic Editor: Tiziano Verri

Copyright © 2015 Mónica Vázquez-Del Mercado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. J. Martyn, M. Kaneki, and S. Yasuhara, “Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms,” Anesthesiology, vol. 109, no. 1, pp. 137–148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. M. J. van Greevenbroek, C. G. Schalkwijk, and C. D. A. Stehouwer, “Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences,” Netherlands Journal of Medicine, vol. 71, no. 4, pp. 174–187, 2013. View at Google Scholar · View at Scopus
  3. Q. Xia and S. F. A. Grant, “The genetics of human obesity,” Annals of the New York Academy of Sciences, vol. 1281, no. 1, pp. 178–190, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. W. K. Chung and R. L. Leibel, “Considerations regarding the genetics of obesity,” Obesity, vol. 16, no. 3, pp. S33–S39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Naukkarinen, A. Rissanen, J. Kaprio, and K. H. Pietiläinen, “Causes and consequences of obesity: the contribution of recent twin studies,” International Journal of Obesity, vol. 36, no. 8, pp. 1017–1024, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Dahlman and P. Arner, “Genetics of adipose tissue biology,” Progress in Molecular Biology and Translational Science, vol. 94, pp. 39–74, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Esterbauer, H. Oberkofler, F. Krempler, and W. Patsch, “Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression,” Genomics, vol. 62, no. 1, pp. 98–102, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Ek, G. Andersen, S. A. Urhammer et al., “Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus,” Diabetologia, vol. 44, no. 12, pp. 2220–2226, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S.-L. Zhang, W.-S. Lu, L. Yan et al., “Association between peroxisome proliferator-activated receptor-γ coactivator-1α gene polymorphisms and type 2 diabetes in southern Chinese population: role of altered interaction with myocyte enhancer factor 2C,” Chinese Medical Journal, vol. 120, no. 21, pp. 1878–1885, 2007. View at Google Scholar · View at Scopus
  10. G. S. Sainani and R. A. Karatela, “Plasma leptin in insulin-resistant and insulin-nonresistant coronary artery disease and its association with cardio-metabolic risk factors among Asian Indians,” Metabolic Syndrome and Related Disorders, vol. 7, no. 4, pp. 335–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Oberkofler, B. Hölzl, H. Esterbauer et al., “Peroxisome proliferator-activated receptor-γ coactivator-1 gene locus: associations with hypertension in middle-aged men,” Hypertension, vol. 41, no. 2, pp. 368–372, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. L. Muller, C. Bogardus, O. Pedersen, and L. Baier, “A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor γ coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians,” Diabetes, vol. 52, no. 3, pp. 895–898, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Francès, F. Verdú, O. Portolés et al., “PPAR-α L162V and PGC-1 G482S gene polymorphisms, but not PPAR-γ P12A, are associated with alcohol consumption in a Spanish Mediterranean population,” Clinica Chimica Acta, vol. 398, no. 1-2, pp. 70–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. I. Lefterova, A. K. Haakonsson, M. A. Lazar, and S. Mandrup, “PPARγ and the global map of adipogenesis and beyond,” Trends in Endocrinology & Metabolism, vol. 25, no. 6, pp. 293–302, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ahmadian, J. M. Suh, N. Hah et al., “PPARgamma signaling and metabolism: the good, the bad and the future,” Nature Medicine, vol. 19, no. 5, pp. 557–566, 2013. View at Google Scholar
  16. Z. E. Floyd and J. M. Stephens, “Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1822, no. 7, pp. 1090–1095, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Cinti, “Transdifferentiation properties of adipocytes in the adipose organ,” American Journal of Physiology: Endocrinology and Metabolism, vol. 297, no. 5, pp. E977–E986, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Yamamoto, S. Kageyama, M. Nemoto et al., “PPARγ2 Pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients,” Hypertension Research, vol. 25, no. 1, pp. 25–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Wang, T. Tahara, T. Arisawa et al., “Polymorphism of peroxisome proliferator-activated receptor gamma is not associated to Japanese ulcerative colitis,” Hepato-Gastroenterology, vol. 55, no. 81, pp. 73–75, 2008. View at Google Scholar · View at Scopus
  20. M. Stumvoll and H. Häring, “The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism,” Diabetes, vol. 51, no. 8, pp. 2341–2347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Gorodezky, C. Alaez, M. N. Vázquez-García et al., “The genetic structure of Mexican Mestizos of different locations: tracking back their origins through MHC genes, blood group systems, and microsatellites,” Human Immunology, vol. 62, no. 9, pp. 979–991, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. World-Health-Organization, Obesity: Preventing and Managing the Global Epidemic, 1st edition, 2012.
  23. H. C. Lukaski, “Body mass index, bioelectrical impedance, and body composition,” Nutrition, vol. 17, no. 1, pp. 55–56, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. H. C. Lukaski, “Regional bioelectrical impedance analysis: applications in health and medicine,” Acta Diabetologica, vol. 40, no. 1, pp. S196–S199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Ness-Abramof and C. M. Apovian, “Waist circumference measurement in clinical practice,” Nutrition in Clinical Practice, vol. 23, no. 4, pp. 397–404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. D. N. Miller, J. E. Bryant, E. L. Madsen, and W. C. Ghiorse, “Evaluation and optimization of DNA extraction and purification procedures for soil and sediment samples,” Applied and Environmental Microbiology, vol. 65, no. 11, pp. 4715–4724, 1999. View at Google Scholar · View at Scopus
  27. M.-O. Guzman-Ornelas, E. Chavarria-Avila, J.-F. Munoz-Valle et al., “Association of ADIPOQ +45T>G polymorphism with body fat mass and blood levels of soluble adiponectin and inflammation markers in a Mexican-Mestizo population,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 5, pp. 369–378, 2012. View at Google Scholar · View at Scopus
  28. F. Guerrero-Romero and M. Rodríguez-Morán, “Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus,” Archives of Medical Research, vol. 34, no. 5, pp. 428–432, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Garaulet, J. J. Hernández-Morante, F. J. Tébar, S. Zamora, and M. Canteras, “Two-dimensional predictive equation to classify visceral obesity in clinical practice,” Obesity, vol. 14, no. 7, pp. 1181–1191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. R. Mamtani and H. R. Kulkarni, “Predictive performance of anthropometric indexes of central obesity for the risk of type 2 diabetes,” Archives of Medical Research, vol. 36, no. 5, pp. 581–589, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  32. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  33. G. H. Hardy, “Mendelian proportions in a mixed population,” Science, vol. 28, no. 706, pp. 49–50, 1908. View at Publisher · View at Google Scholar · View at Scopus
  34. E. P. de Oliveira, M. D. D. A. de Lima, and M. L. A. de Souza, “Metabolic syndrome, its phenotypes, and insulin resistance by HOMA-IR,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 9, pp. 1506–1515, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Benozzi, F. Ordonez, N. Polini, C. Alvarez, J. Sellest, and R. I. Coniglio, “Insulin-resistance and metabolic syndrome in patients with coronary heart disease defined by angiography,” Medicina, vol. 69, no. 2, pp. 221–228, 2009. View at Google Scholar · View at Scopus
  36. R. Dalan, M. Jong, S. P. Chan et al., “High-sensitivity C-reactive protein concentrations among patients with and without diabetes in a multiethnic population of Singapore: CREDENCE Study,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 3, pp. 187–195, 2010. View at Google Scholar
  37. S. H. Chu, M. K. Lee, K. Y. Ahn et al., “Chemerin and adiponectin contribute reciprocally to metabolic syndrome,” PLoS ONE, vol. 7, no. 4, Article ID e34710, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Tsuriya, H. Morita, T. Morioka et al., “Significant correlation between visceral adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects,” Internal Medicine, vol. 50, no. 22, pp. 2767–2773, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Ou, X. Liu, Y. Shen et al., “Association of CVD candidate gene polymorphisms with ischemic stroke and cerebral hemorrhage in chinese individuals,” PLoS ONE, vol. 9, no. 8, Article ID e105516, 2014. View at Publisher · View at Google Scholar
  40. D. Vasudevan, A. L. Stotts, S. Mandayam, and L. A. Omegie, “Comparison of BMI and anthropometric measures among South Asian Indians using standard and modified criteria,” Public Health Nutrition, vol. 14, no. 5, pp. 809–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Harbron, L. van der Merwe, M. G. Zaahl, M. J. Kotze, and M. Senekal, “Fat mass and obesity-associated (FTO) gene polymorphisms are associated with physical activity, food intake, eating behaviors, psychological health, and modeled change in body mass index in overweight/obese Caucasian adults,” Nutrients, vol. 6, no. 8, pp. 3130–3152, 2014. View at Publisher · View at Google Scholar
  42. M. Chandalla, P. Lin, T. Seenivasan et al., “Insulin resistance and body fat distribution in South Asian men compared to Caucasian men,” PLoS ONE, vol. 2, no. 8, article e812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. N. M. Kaplan, “The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension,” Archives of Internal Medicine, vol. 149, no. 7, pp. 1514–1520, 1989. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Fulop, D. Tessier, and A. Carpentier, “The metabolic syndrome,” Pathologie Biologie, vol. 54, no. 7, pp. 375–386, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Karastergiou and V. Mohamed-Ali, “The autocrine and paracrine roles of adipokines,” Molecular and Cellular Endocrinology, vol. 318, no. 1-2, pp. 69–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Galic, J. S. Oakhill, and G. R. Steinberg, “Adipose tissue as an endocrine organ,” Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 129–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. C. de Luca and J. M. Olefsky, “Inflammation and insulin resistance,” FEBS Letters, vol. 582, no. 1, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Chung-Jen, B. A. Beamer, C. Negri et al., “Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation,” Biochemical and Biophysical Research Communications, vol. 241, no. 2, pp. 270–274, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Kuliczkowska, A. Filus, A. Trzmiel et al., “PPAR-γ2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw,” Endokrynologia Polska, vol. 59, no. 4, pp. 312–315, 2008. View at Google Scholar · View at Scopus
  51. N. A. West, M. N. Haan, and H. Morgenstern, “The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study,” Neurobiology of Aging, vol. 31, no. 5, pp. 741–746, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ereqat, A. Nasereddin, K. Azmi, Z. Abdeen, and R. Amin, “Impact of the pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the palestinian type 2 diabetic patients,” PPAR Research, vol. 2009, Article ID 874126, 5 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Aoyagi, S. Nagata, T. Kudo et al., “Peroxisome proliferator-activated receptor γ 2 mutation may cause a subset of ulcerative colitis,” Pediatrics International, vol. 52, no. 5, pp. 729–734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. O. Atug, V. Tahan, F. Eren et al., “Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARγ) gene in inflammatory bowel disease,” Journal of Gastrointestinal and Liver Diseases, vol. 17, no. 4, pp. 433–437, 2008. View at Google Scholar · View at Scopus
  55. U. K. Shrestha, O. Karimi, J. B. A. Crusius et al., “Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 16, no. 2, pp. 312–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Duran-Gonzalez, I. Ortiz, E. Gonzales et al., “Association study of candidate gene polymorphisms and obesity in a young Mexican-American population from South Texas,” Archives of Medical Research, vol. 42, no. 6, pp. 523–531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. B. I. Estrada-Velasco, M. Cruz, V. Madrid-Marina, G. A. Martínez-Nava, J. Gomez-Zamudio, and A. I. Burguete-García, “IRS1, TCF7L2, ADRB1, PPARG, and HHEX polymorphisms associated with atherogenic risk in Mexican population,” BioMed Research International, vol. 2013, Article ID 394523, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. Gamboa-Meléndez, A. Huerta-Chagoya, H. Moreno-Macías et al., “Contribution of common genetic variation to the risk of type 2 diabetes in the Mexican Mestizo population,” Diabetes, vol. 61, no. 12, pp. 3314–3321, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. L. E. Martínez-Gómez, M. Cruz, G. A. Martínez-Nava et al., “A replication study of the IRS1, CAPN10, TCF7L2, and PPARG gene polymorphisms associated with type 2 diabetes in two different populations of Mexico,” Annals of Human Genetics, vol. 75, no. 5, pp. 612–620, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. J. P. Berger, T. E. Akiyama, and P. T. Meinke, “ARs-ARtherapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005. View at Google Scholar
  62. B. Fève, “Adipogenesis: cellular and molecular aspects,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 19, no. 4, pp. 483–499, 2005. View at Google Scholar
  63. M. Guerro-Millo, “Adipose tissue and adipokines: for better or worse,” Diabetes & Metabolism, vol. 30, no. 1, pp. 13–19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Mansour, “The roles of peroxisome proliferator-activated receptors in the metabolic syndrome,” in Progress in Molecular Biology and Translational Science, vol. 121, chapter 7, pp. 217–266, Elsevier, 2014. View at Publisher · View at Google Scholar
  65. F. A. Monsalve, R. D. Pyarasani, F. Delgado-Lopez, and R. Moore-Carrasco, “Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases,” Mediators of Inflammation, vol. 2013, Article ID 549627, 18 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Bhat, A. Koul, E. Rai, S. Sharma, and M. K. Dhar, “PGC-1α Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control study,” Human Genetics, vol. 121, no. 5, pp. 609–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Clark, S. Reddy, K. Zheng, R. A. Betensky, and D. K. Simon, “Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease,” BMC Medical Genetics, vol. 12, article 69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Ginevičiene, V. Pranculis, V. Jakaitiene, V. Milašius, and V. Kučinskas, “Genetic variation of the human ACE and ACTN3 genes and their association with functional muscle properties in Lithuanian elite athletes,” Medicina, vol. 47, no. 5, pp. 284–290, 2011. View at Google Scholar · View at Scopus
  69. E. Ingelsson, L. Bennet, M. Ridderstråle, M. Söderström, L. Råstam, and U. Lindblad, “The PPARGC1A Gly482Ser polymorphism is associated with left ventricular diastolic dysfunction in men,” BMC Cardiovascular Disorders, vol. 8, article 37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. J. H. Kim, H. D. Shin, B. L. Park et al., “Peroxisome proliferator-activated receptor gamma coactivator 1 alpha promoter polymorphisms are associated with early-onset type 2 diabetes mellitus in the Korean population,” Diabetologia, vol. 48, no. 7, pp. 1323–1330, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. M.-C. Hsieh, K.-D. Lin, K.-J. Tien et al., “Common polymorphisms of the peroxisome proliferator-activated receptor-γ (Pro12Ala) and peroxisome proliferator-activated receptor-γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus,” Metabolism: Clinical and Experimental, vol. 59, no. 8, pp. 1139–1144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Okauchi, H. Iwahashi, K. Okita et al., “PGC-1α Gly482Ser polymorphism is associated with the plasma adiponectin level in type 2 diabetic men,” Endocrine Journal, vol. 55, no. 6, pp. 991–997, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Andrulionytè, J. Zacharova, J.-L. Chiasson, and M. Laakso, “Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial,” Diabetologia, vol. 47, no. 12, pp. 2176–2184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Liang and W. F. Ward, “PGC-1α: a key regulator of energy metabolism,” American Journal of Physiology: Advances in Physiology Education, vol. 30, no. 4, pp. 145–151, 2006. View at Publisher · View at Google Scholar · View at Scopus